Nautilus Biotechnolgy
NAUT
81 hedge funds and large institutions have $235M invested in Nautilus Biotechnolgy in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 13 closing their positions.
529% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $324K
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
14.95% more ownership
Funds ownership: 33.02% → 47.97% (+15%)
13% more funds holding
Funds holding: 72 → 81 (+9)
4% less capital invested
Capital invested by funds: $245M → $235M (-$10.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
+$7.76M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.74M |
| 3 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$2.8M |
| 4 |
CGL
Clarius Group LLC
Seattle,
Washington
|
+$2.19M |
| 5 |
PA
Perceptive Advisors
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.91M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$4.61M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.68M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$1.93M |
| 5 |
ABG
Ally Bridge Group
New York
|
-$1.47M |
NAUT Hedge Fund Activity: Q4 2021 in Review
81 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q4 2021, worth a combined $235M — down 4.2% from $245M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NAUT positions and 13 closed out — a net gain of 9 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was ArchPoint Investors, opening a new position worth an estimated $7.76M. The largest seller was Federated Hermes, exiting entirely with an estimated $4.91M sold.
- 81 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q4 2021, up from 72 in Q3 2021.
- Funds reported $235M of Nautilus Biotechnolgy stock for Q4 2021, down 4.2% quarter-over-quarter.
- 22 funds opened new Nautilus Biotechnolgy positions in Q4 2021 and 13 closed out, a net change of +9 holders.
- The largest Nautilus Biotechnolgy buyer in Q4 2021 was ArchPoint Investors, an estimated $7.76M added.
- The largest Nautilus Biotechnolgy seller in Q4 2021 was Federated Hermes, an estimated $4.91M sold.
Based on aggregated 13F filings for Q4 2021.